Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort
Annals of Hematology · 2025-03 · 104 (3) · 1587-1596
DOI: 10.1007/s00277-025-06326-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 01.04.2025. Verfasst von Benjamin Lebecque und 15 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie Biologique, CHU Estaing, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Janus Kinase 2, Myeloproliferative Disorders, Alleles, Mutation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Since 2008, the JAK2V617F mutation has been key for diagnosing myeloproliferative neoplasms (MPN) according to the World Health Organization criteria. However, the clinical and biological significance of low JAK2V617F variant allelic fraction (VAF) remains poorly understood. To address this, we performed a comprehensive molecular characterization of a monocentric real-world retrospective cohort of MPN patients with low JAK2V617F VAF, diagnosed between 2007 and 2019. Our analysis revealed that 46.3% of these cases had additional driver mutations into JAK2, CALR, and MPL genes associated with very low JAK2V617F VAF (median: 0.09%). Furthermore, next-generation sequencing of cases without these driver mutations showed that 67.7% harbored other mutations, including low VAF CALR mutations, as well as TP53 alterations or predisposition genes. These findings highlight the importance of comprehensive molecular analysis in conjunction with bone marrow biopsy (BMB). Notably, we found a negative BMB did not exclude an MPN diagnosis, and molecular results confirmed MPN in some patients even without BMB evidence. Integrating BMB findings, molecular data, and low JAK2V617F VAF with clinical assessments highlights the potential for misdiagnoses, especially in cases that might overlap with age-related clonal hematopoiesis. Our study emphasizes the need for extensive molecular investigation in cases of low JAK2V617F MPN to ensure accurate diagnosis and appropriate management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Hématologie Biologique, CHU Estaing, Clermont-Ferrand, France.
- Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, Clermont-Ferrand, France.
- Service de thérapie cellulaire et hématologie clinique adulte, CHU Estaing, Clermont-Ferrand, France.
- Médecine interne, Jacques Lacarin, Vichy, France.
- Oncologie médicale, C.H. Emile Roux, Le Puy-en-Velay, France.
- Médecine interne, CH Aurillac, Aurillac, France.
Zitieren
APA
Lebecque, B., Croizier, C., Tassin, T., Louis, E., Tribalat, N., Bombardier, W., Grandjean, A. P., Pante, V., Monjanel, H., Bouillon-Minois, J. B., Martel, R., Ledoux-Pilon, A., Boiret-Dupré, N., Renzis, B., Berger, M. G., & Bourgne, C. (2025). Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort. Annals of Hematology, 104(3), 1587-1596. https://doi.org/10.1007/s00277-025-06326-w
Vancouver
Lebecque B, Croizier C, Tassin T, Louis E, Tribalat N, Bombardier W, et al. Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort. Annals of Hematology. 2025;104(3):1587-1596. doi:10.1007/s00277-025-06326-w
BibTeX
@article{Lebecque2025,
author = {Lebecque, Benjamin and Croizier, Carolyne and Tassin, Thomas and Louis, Esteban and Tribalat, Nathalie and Bombardier, William and Grandjean, Anne-Pascale and Pante, Vanessa and Monjanel, Hélène and Bouillon-Minois, Jean-Baptiste and Martel, Rémi and Ledoux-Pilon, Albane and Boiret-Dupré, Nathalie and Renzis, Benoit De and Berger, Marc Gabriel and Bourgne, Céline},
title = {Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort},
journal = {Annals of Hematology},
year = {2025},
volume = {104},
number = {3},
pages = {1587--1596},
doi = {10.1007/s00277-025-06326-w}
}
EUVIMED